medicalxpress.com
A recent study led by the University of Barcelona uncovers a molecular mechanism that could redefine strategies to eliminate senescent cells in cancer patients post-treatment.
Understanding this mechanism is significant as it presents new opportunities to enhance recovery outcomes by eliminating senescent cells, which could otherwise lead to cancer relapse or premature aging.
The University of Barcelona's recent research highlights a molecular mechanism involving the BCL-2 family proteins that could drive the development of new strategies to eliminate senescent cells in cancer patients. These cells, which resist death and accumulate after treatments like chemotherapy, can hinder recovery by potentially regenerating tumors or causing early aging. By analyzing melanoma cells, researchers identified the anti-apoptotic role of the BCL-XL protein, which interacts with the HRK protein to inhibit cell death. This finding opens promising avenues for developing therapies that target BCL-XL to improve patient outcomes.
Senescent cells pose a risk to recovery by promoting cancer relapse and premature aging.
Senescent cells are resistant to death and can accumulate post-therapy, potentially regenerating tumors.
Eliminating these cells could improve recovery and reduce risks of cancer resurgence.
Causal logic suggests that removing senescent cells will prevent them from causing negative outcomes post-treatment.
Senescence is a process where cells stop dividing but remain metabolically active, often triggered by stressors like chemotherapy and radiotherapy. These cells resist apoptosis, the programmed cell death, and accumulate if not removed, posing significant risks for cancer patients.
Researchers from the University of Barcelona led by Professor Joan Montero have focused on understanding how senescent cells survive post-cancer treatment, particularly in melanoma—a skin cancer affecting melanocytes. Their persistence can lead to tumor regrowth and other complications.
"Understanding the survival mechanisms of senescent cells will help open up new therapeutic approaches in the field of cancer control," said Professor Montero. This emphasis on survival mechanisms underlines the importance of targeted therapeutic strategies.
BCL-2 proteins are crucial in regulating cell death, specifically in senescent cells.
The BCL-2 family proteins, particularly BCL-XL, play a key role in inhibiting apoptosis in senescent cells.
Targeting these proteins may allow for the selective elimination of harmful senescent cells.
By understanding the mechanism of action of BCL-2 proteins, specific interventions can be deduced to target senescent cells.
BCL-2 family proteins are pivotal in managing cell death processes, with different members either promoting or inhibiting apoptosis. In the context of melanoma, these proteins, especially BCL-XL, exhibit increased activity, which helps senescent cells to evade death post-therapy.
The research employed BH3 profiling to study these proteins' influence on senescent cell survival. They discovered a significant role of BCL-XL in protecting cells from apoptosis, thus facilitating their persistence in the body.
According to Clara Alcon, "This is the first time that the molecular basis for the anti-apoptotic adaptation of BCL-XL in senescence has been described," highlighting a novel area for therapeutic exploration.
Therapies targeting BCL-XL could effectively eliminate senescent cells, improving treatment outcomes.
Targeting BCL-XL offers a promising approach to counteract the adverse effects of senescent cells in cancer therapy.
By blocking BCL-XL, senescent cells can be driven towards apoptosis, reducing relapse risks.
If BCL-XL is responsible for senescence survival, then inhibiting it should lead to cell death, reducing negative outcomes.
The research opens the door for developing senolytic drugs that can specifically target and inhibit BCL-XL, forcing the resistant senescent cells into apoptosis. This approach could significantly enhance the efficacy of cancer treatments.
Potential therapeutic strategies identified include using compounds like A-1331852, navitoclax, or PROTAC strategies that focus on BCL-XL. These therapies may offer new solutions to prevent tumor regrowth and improve patient recovery.
Professor Montero stated, "This discovery opens the way to develop new therapies that prevent the down-regulation of the HRK protein or displace the binding of BCL-XL to BAK to be used as senolytics," emphasizing the potential for targeted intervention.
Alcon, C., et al. (2024). HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells. Cell Death & Differentiation. DOI: 10.1038/s41418-024-01417-z